STOCKS TUMBLE AS RISING TREASURY YIELDS RATTLE NERVES

Rising treasury yields have hit a level expected to hurt 'lower-quality, riskier and expensive stocks'

BMY Jan 2026 40.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

5.85

0.00

(0.00%)

As of 01:04PM EDT. Market open.

Loading interactive chart...

Zacks
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., May 29, 2024--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line...
ACCESSWIRE
ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 /Originally published on Bristol Myers Squibb News & Perspectives Globally, communities are struggling to support growing healthcare needs. This is especially true in regions with limited financial resources, ...